Pyxis Oncology: Wells Fargo Sees 2 Billion USD Peak Revenue for New Cancer Drug MICVO
Reading Time: 3 minutes
Wells Fargo raises the price target for Pyxis Oncology (PYXS) to 19 USD based on recent study data, with a revenue potential of 2 billion USD. The business model focuses on antibody-drug conjugates (ADCs) for targeted oncology. Strategic Positioning in Targeted Oncology Pyxis Oncology (PYXS) develops novel cancer therapies, primarily antibody-drug conjugates (ADCs). These deliver toxic agents directly into tumor cells while sparing healthy tissue. The company is thus addressing the structural growth trend of personalized medicine. The main...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
